All In Biotech

Drug Trial Radar · NCT04965493

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)

Last checked: Nov 19, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Sep 20, 2021

Primary completion

Oct 2026

Study completion Oct 2027

Sponsor

Lead sponsor
Loxo Oncology, Inc.Eli Lilly (LLY)
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Jul 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years.

Conditions

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Interventions

  • PirtobrutinibDrug

    Oral

  • VenetoclaxDrug

    Oral

  • RituximabDrug

    Intravenous (IV)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate progression-free survival (PFS) of pirtobrutinib plus venetoclax and rituximab (Arm A) compared to venetoclax and rituximab (Arm B)Time frame: Up to approximately 5 years

Locations

176 sites in 23 countries. Site status is shown where the registry gives one.

  • Ironwood Physicians, Ironwood Cancer and Research Centers

    Chandler, Arizona

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • University of California Irvine Medical Center

    Orange, California

  • Scripps Mercy Hospital

    San Diego, California

  • Providence Medical Foundation

    Santa Rosa, California

  • Stamford Hospital

    Stamford, Connecticut

  • Florida Cancer Specialists

    Fort Myers, Florida

  • Cancer Specialists of North Florida -St Augustine

    Saint Augustine, Florida

  • Florida Cancer Specialists East

    West Palm Beach, Florida

  • Mission Cancer and Blood

    Des Moines, Iowa

  • Pikeville Medical Center, Inc.

    Pikeville, Kentucky

  • American Oncology Partners of Maryland, PA

    Bethesda, Maryland

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • St. Joseph Mercy Hospital

    Ann Arbor, Michigan

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Research Medical Center

    Kansas City, Missouri

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey

  • The Mount Sinai Hospital

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Novant Cancer Institute Charlotte

    Charlotte, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Regional Medical Oncology Center

    Wilson, North Carolina

  • Oncology Hematology Care Inc

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • The James Cancer Hospital

    Columbus, Ohio

  • Oncology Associates of Bridgeport P.C.

    Eugene, Oregon

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • Sarah Cannon Research Institute SCRI

    Nashville, Tennessee

  • Tennessee Oncology PLLC

    Nashville, Tennessee

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • USO - Texas Oncology - San Antonio

    San Antonio, Texas

  • University of Virginia Health System

    Charlottesville, Virginia

  • Virginia Cancer Specialists, PC - Lee Highway

    Fairfax, Virginia

  • Virginia Commonwealth University Massey Cancer Center

    Richmond, Virginia

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • Swedish Cancer Institute; STE 1020

    Seattle, Washington

Showing 40 of 176 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.